Patents by Inventor William S. Denney

William S. Denney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders
    Patent number: 9370516
    Abstract: The present invention relates to methods of treating sleep disorders in patients comprising administration of a ghrelin receptor inverse agonist or antagonist. The invention also includes methods of treating sleep disorders comprising the administration of a pharmaceutical composition comprising a ghrelin receptor inverse agonist or antagonist and at least one pharmaceutically acceptable carrier, diluent, or excipient.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: June 21, 2016
    Assignee: Pfizer Inc.
    Inventors: William S. Denney, Margaret Jackson, Gabriele Sonnenberg
  • USE OF GHRELIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR TREATING SLEEP DISORDERS
    Publication number: 20150119381
    Abstract: The present invention relates to methods of treating sleep disorders in patients comprising administration of a ghrelin receptor inverse agonist or antagonist. The invention also includes methods of treating sleep disorders comprising the administration of a pharmaceutical composition comprising a ghrelin receptor inverse agonist or antagonist and at least one pharmaceutically acceptable carrier, diluent, or excipient.
    Type: Application
    Filed: May 21, 2013
    Publication date: April 30, 2015
    Applicant: Pfizer Inc.
    Inventors: William S. Denney, Margaret Jackson, Gabriele Sonnenberg
  • COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONISTS AND AN ANTIMUSCARINIC AGENT
    Publication number: 20120202819
    Abstract: Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective M2 antagonist. Such combination therapy provides improved efficacy and/or reduced side effects.
    Type: Application
    Filed: September 27, 2010
    Publication date: August 9, 2012
    Applicant: Merck Sharp & Dohme Corporation
    Inventors: Scott D. Edmondson, Mary Struthers SinhaRroy, Hiroshi Nagabukuro, William S. Denney, Tara F. Frenki